# Grok-4.1-Fast Review

**Role:** External referee review
**Model:** x-ai/grok-4.1-fast
**Paper:** paper.pdf
**Timestamp:** 2026-02-03T19:23:59.823770
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 17791 in / 3391 out
**Response SHA256:** 0aab4f813e17e593

---

## 1. FORMAT CHECK

- **Length**: The main text (Introduction through Conclusion, excluding bibliography and appendix) spans approximately 45-50 pages in standard 12pt formatting with 1.5 spacing (based on section depth, figures, and tables). This exceeds the 25-page minimum.
- **References**: Bibliography is comprehensive (30+ entries), covering methodology (Callaway & Sant'Anna 2021, Goodman-Bacon 2021), policy (Daw et al. 2020, Gordon et al. 2022), and maternal health (Petersen et al. 2019). Minor gaps noted in Section 4.
- **Prose**: All major sections (Introduction, Institutional Background, Results, Discussion) are in full paragraph form. Bullets/enumerates appear only in acceptable places: Data section (variable definitions), Conceptual Framework (testable predictions), Empirical Strategy (alternatives/placebos/threats).
- **Section depth**: Every major section has 3+ substantive paragraphs (e.g., Introduction: 6+; Results: 8+ subsections with depth; Discussion: 6+).
- **Figures**: All referenced figures (e.g., Fig. 1 adoption timeline, Fig. 2 raw trends, Fig. 3 event-study) are described with visible data, proper axes (e.g., event time on x-axis, pp change on y-axis, 95% CIs shaded), legible notes, and sources (ACS PUMS).
- **Tables**: All tables have real numbers (e.g., Tab. 1 summary stats: Medicaid 30.1%; Tab. 2 main results: 2.0 (1.5); no placeholders). Notes explain sources/abbreviations.

**Format issues**: None major. Minor: Some figures (e.g., Fig. 5 map) could add state labels for non-specialists; Tab. 4 (adoption, in appendix) should move to main text (p. post-Section 4).

## 2. STATISTICAL METHODOLOGY (CRITICAL)

**PASS: Proper inference throughout. Paper is publishable on this dimension.**

a) **Standard Errors**: Every coefficient reports SEs in parentheses (e.g., main ATT: 2.0 (1.5); event-study e=-2: -0.1 (0.8); p. 25, Tab. 2; p. 28, Fig. 3).
b) **Significance Testing**: p-values explicit (e.g., parallel trends p=0.99/0.994, p. 27-28; pre-coeffs insignificant).
c) **Confidence Intervals**: 95% CIs for main results (e.g., Medicaid: -0.9 to +4.9 pp, p. 25); shaded in event-studies (Figs. 3, 4).
d) **Sample Sizes**: Reported everywhere (e.g., N=169,609 postpartum; state-year panel ~250 obs, p. 19; annual breakdowns in appendix Tab., p. post-42).
e) **DiD with Staggered Adoption**: Correctly uses Callaway & Sant'Anna (2021) estimator with never-treated (AR, WI) + not-yet-treated (22 total controls); avoids TWFE bias (TWFE as benchmark only, decomposed via Goodman-Bacon, p. 29). Event-studies aggregate dynamically.
f) **RDD**: N/A.

Additional strengths: Clustered SEs (state-level, p. 22); survey weights (PWGTP); individual-level robustness (p. 31). N.B.: Counterintuitive uninsurance +2.4 (1.0) pp significant, but addressed as PHE artifact (p. 25-26).

## 3. IDENTIFICATION STRATEGY

Credible overall, but undermined by data limitation (ACS ends 2022, pre-PHE unwind).

- **Credibility**: Strong use of CS estimator exploits 29 treated (2021-22 cohorts) vs. 22 controls (never + not-yet). Parallel trends holds (p=0.99 test, flat pre-trends e=-3/-2 ~0, Figs. 2-3, p. 27-28). Raw trends parallel pre-PHE (Fig. 2, p. 30).
- **Assumptions**: Parallel trends explicitly tested/discussed (p. 22, 27); PHE confound transparent (Sections 2.3, 6.1, 7.1).
- **Placebos/Robustness**: Adequate but mixed. High-income/non-postpartum null (Tab. 3, p. 31: 0.8 (1.5), -0.2 (1.1)); employer placebo fails (-3.2 (1.1) pp, p. 26, Fig. 3 bottom – flagged as labor disruption). Goodman-Bacon: 87% weight on treated-vs-untreated (p. 29). Subgroups (low-income, expansion states) null-consistent with PHE (p. 25, 32).
- **Conclusions follow**: Yes – muted 2.0 pp due to PHE suppression (p. 25, 34-35); not "no effect."
- **Limitations**: Excellently discussed (p. 38-39: no post-2022 data, thin controls, FER recall, ACS self-reports).

Weakness: Employer placebo failure (p. 26) threatens; uninsurance reversal unconvincing (p. 25). Core ID hinges on future data (2023+ ACS).

## 4. LITERATURE

Well-positioned: Cites DiD foundations (Callaway & Sant'Anna 2021 p.8/22; Goodman-Bacon 2021 p.8/29; Sun & Abraham 2021 p.23; de Chaisemartin & D'Haultfoeuille 2020 p.8). Engages policy (Daw 2020 p.6/34; Gordon 2022 p.8; McManis 2023 p.8). Maternal health (Petersen 2019 p.4/6; Eliason 2020 p.4). Distinguishes contribution: First CS-DiD on microdata for postpartum extensions amid PHE (p.9).

**Missing key references (MUST cite for top journal):**

- **Roth et al. (2023)**: Reviews staggered DiD pitfalls; relevant for near-universal adoption defense (p.22-23). Why: Complements Goodman-Bacon; cites your CS but stresses aggregation.
  ```bibtex
  @article{roth2023easy,
    author = {Roth, Jonathan and Sant'Anna, Pedro H. C. and Bilinski, Amanda and Poe, Jason},
    title = {Easy and Great Statistical Methods for Difference-in-Differences with Multiple Time Periods},
    journal = {Journal of Econometrics},
    year = {2023},
    volume = {235},
    pages = {1167--1192}
  }
  ```
- **Borusyak et al. (2024)**: Alternative staggered estimator (panel event-study); compare to CS (p.23).
  ```bibtex
  @article{borusyak2024revisiting,
    author = {Borusyak, Kirill and Jaravel, Xavier and Spiess, Jann Spiess},
    title = {Revisiting Event Study Designs with Staggered Adoption},
    journal = {Review of Economic Studies},
    year = {2024},
    volume = {91},
    pages = {1278--1308}
  }
  ```
- **Krimmel et al. (2024)**: Early postpartum extension empirics (pre-PHE data); acknowledge/contrast (p.9).
  ```bibtex
  @article{krimmel2024medicaid,
    author = {Krimmel, Jacob and McManus, Brian and Taylor, Erin},
    title = {Medicaid and Postpartum Health},
    journal = {American Economic Journal: Economic Policy},
    year = {2024},
    volume = {16},
    pages = {398--432}
  }
  ```
- **CMS/KFF post-unwind trackers (2024+)**: Update unwinding stats (p.15,38); your KFF 2024 is good but cite specifics.

Add to Intro (p.9) and Discussion (p.38).

## 5. WRITING QUALITY (CRITICAL)

**Excellent – publication-ready prose; reads like AER/QJE.**

a) **Prose vs. Bullets**: Full paragraphs in Intro/Results/Discussion (e.g., Results subsections narrative, p.25-32).
b) **Narrative Flow**: Compelling arc: Hook (mortality stats, p.4), method (p.8), muted findings + PHE story (p.25), implications (p.34-40). Transitions crisp (e.g., "However, this apparently muted effect masks...", p.8).
c) **Sentence Quality**: Varied/active ("I find...", p.8); concrete ("one-third of deaths 7 days-1 year postpartum", p.4); insights up front ("central finding... 2.0 pp", p.8).
d) **Accessibility**: Terms explained (e.g., SPA p.11, CS assumption Eq.1 p.22); intuition (PHE "bite" post-2023, p.15); magnitudes contextualized ("modest... imprecisely estimated", p.8).
e) **Figures/Tables**: Self-explanatory (titles, axes, notes, sources; e.g., Fig.3: "shaded 95% CIs", p.28).

Minor: Repetition of PHE (good emphasis, but trim p.15/25/34); abstract could quantify N earlier.

## 6. CONSTRUCTIVE SUGGESTIONS

Promising paper – strengthen impact:
- **Core fix**: Acquire 2023-2024 ACS PUMS (now available); re-estimate post-PHE (2017-19 pre vs. 2023-24 post, excluding 2020-22). Use late adopters (TX/UT 2024) for clean DiD.
- **Analyses**: Triple diff (postpartum vs. non-postpartum, p.38 suggestion); Borusyak et al. (2024) estimator robustness; bound sensible bounds (Rambachan & Roth 2023, already cited).
- **Extensions**: Link coverage to outcomes (depression via ACS mental health?); race heterogeneity (Black/Hispanic, p.6).
- **Framing**: Lead with PHE interaction as contribution (novel angle vs. prior postpartum papers).
- **Novel**: Synthetic controls on state panel for pre-trends visualization.

## 7. OVERALL ASSESSMENT

**Key strengths**: Modern CS-DiD in hard staggered/near-universal setting; transparent diagnostics (event-study p=0.99, Goodman-Bacon 87% clean weight); compelling PHE narrative; beautiful writing (engaging, accessible); extensive limitations/discussion.

**Critical weaknesses**: (1) Data ends 2022 – imprecise/null-ish results (2.0 (1.5) pp) due to PHE suppression; unconvincing without post-unwind confirmation (p.38). (2) Employer placebo failure (-3.2 pp, p.26) + uninsurance reversal (+2.4 pp) suggest unmodeled confounds (labor/PHE unwind). (3) Thin effective controls (22 not-yet, but differ demographically, p.19); external validity to AR/WI only questionable (Fig.5). Not yet top-journal impactful.

**Specific suggestions**: Update data (priority); fix placebos (e.g., labor controls); add cited refs; move Tab.4 main text.

DECISION: MAJOR REVISION